Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.

Uzun S., Bilgiç Temel A., Akman Karakaş A., Ergün E., Özkesici B., Eskiocak A. H., ...More

International journal of dermatology, vol.55, no.12, pp.1362-1368, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55 Issue: 12
  • Publication Date: 2016
  • Doi Number: 10.1111/ijd.13400
  • Journal Name: International journal of dermatology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1362-1368
  • Akdeniz University Affiliated: Yes


BackgroundPemphigus vulgaris (PV) is a severe, chronic, and potentially life-threatening autoimmune blistering disease that affects the skin and mucous membranes. Rituximab is a monoclonal anti-CD20 antibody which has been used increasingly in the therapy of PV.